1 insider bought €394k of shares over the last 90 days, the latest by 朱忠远, filed 07 Sept 2026.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 26 declarations
Duality Biotherapeutics, Inc. (B), a health care company listed in Hong Kong with a market capitalisation of HKD 15.60 billion, has a recent record of 26 filings, published between April 29, 2025 and October 2, 2026 and filed by 4 directors. Insiders hold 19.2% of the capital.
Sales are heavier than purchases: 6 sales worth EUR 14,118,565, median EUR 1,357,162, against 8 purchases worth EUR 1,534,327, median EUR 194,064, or 57% purchases among open-market trades. The two largest sales are by 张韶壬, EUR 5,938,562 on January 16, 2026, and by 司文, EUR 3,897,692 on January 12, 2026. 朱忠远, who filed 15 times, 8 purchases and 2 sales, sold EUR 1,360,769 on December 16, 2025 and made the three largest purchases: EUR 248,444 on May 21, 2026, EUR 201,989 on September 3, 2026 and EUR 200,585 on June 17, 2026.
Hua Haiqing filed 5 times, 2 of them sales. The record also holds 12 filings of another kind. The year 2025 has 9 filings, 2026 has 17. Over the last twelve months: 21 filings, 8 purchases, 6 sales. The median publication delay is 3 days.